CEN-tools
CEN-tools maps context-specific gene essentiality by constructing essentiality networks from genome-scale CRISPR screens to identify genetic dependencies across tissue origin, mutation profiles, expression levels, and drug-response contexts.
Key Features:
- Genome-scale CRISPR screen integration: Uses genome-scale CRISPR screen data as the primary input for downstream analyses.
- Integration of contextual data: Associates essentiality with specific contexts including tissue origin, mutation profiles, gene expression levels, and drug-response metrics.
- Dependency networks (CENs): Constructs context-specific essentiality networks that represent gene–context associations and variation in essentiality across contexts.
- Integration with protein-protein interaction networks: Combines CENs with protein-protein interaction data to reveal context-dependent cellular pathways, particularly in cancer cells.
Scientific Applications:
- Systematic identification of genetic dependencies: Enables systematic mapping of genes that are essential in specific biological contexts.
- Targeted gene function analysis: Facilitates focused investigation of individual genes to determine their context-specific essentiality and roles.
- Novel therapeutic interventions: Supports identification of context-dependent pathways and targets that can inform development of context-specific therapeutic strategies.
Methodology:
CEN-tools uses genome-scale CRISPR screen data to construct context-specific essentiality networks (CENs) and integrates these networks with protein-protein interaction data to reveal context-dependent cellular dependencies, with emphasis on cancer research.
Topics
Details
- License:
- GPL-3.0
- Tool Type:
- command-line tool
- Programming Languages:
- Python
- Added:
- 1/18/2021
- Last Updated:
- 2/10/2021
Operations
Publications
Sharma S, Dincer C, Weidemüller P, Wright GJ, Petsalaki E. CEN-tools: An integrative platform to identify the ‘contexts’ of essential genes. Unknown Journal. 2020. doi:10.1101/2020.05.10.087668.